Our previous meta-analysis demonstrated that DPP-4 inhibitor and GLP-1 Ras may help improve exercise capacity in HF patients with or without diabetes (29), but these trials showed no improvement in LVEF (30–32), except in a trial with a small sample size (33). This evidence concerns the gene GLP1R and diabetes mellitus.